Venture Capital News: Fathom Therapeutics Scores $47 Million Series A
2026-04-27
Tweet
NEW YORK, NY, Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to design novel drug molecules by predicting their behavior inside living cells, announced an oversubscribed $47 million Series A financing.
Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to design novel drug molecules by predicting their behavior inside living cells, announced an oversubscribed $47 million Series A financing. Sutter Hill Ventures led the round, with participation from Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures, among others.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
